Biotech Values

[DewDiligence]

ABT +2%/AH on FDA approval of FreeStyle Libre continuous glucose-monitoring system:

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm577890.htm

FreeStyle Libre was already approved in all major countries except the US (where medical-device approvals tend to be slowest), but FDA approval will move the needle even for a company as large as ABT.

Please see #msg-128721238 for a summary of the real-world data on this device.

Competitor DXCM is -6%/AH on this news.